Consequences of Discontinuing a 4/6 Cyclin D-Dependent Kinase Inhibitor During Endocrine Treatment in Hormone-Sensitive Metastatic Breast Cancer Patients in the Context of the COVID-19 Outbreak.

Date publication

octobre 2022

Journal

Clinical breast cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr LIMACHER Jean-Marc , Pr PETIT Thierry , Pr VELTEN Michel

Tous les auteurs :
Martin S, Pflumio C, Trensz P, Schaff-Wendling F, Weindling MK, Fischbach C, Pierard L, Limacher JM, Nader R, Velten M, Petit T

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36414498

Résumé

The impact of some hasty medical decision made during the first wave of the Coronavirus Disease 2019 (COVID-19) remains unknown. We have evaluated the consequences of one of these precautionary measures: the withdrawal of the cyclin D-dependent kinases 4/6 inhibitor (CDK4/6i) in patients whose metastatic disease was controlled by a combination of endocrine treatment and CDK 4/6i.

Mots clés

CDK4/6 inhibitors, COVID-19, Disease progression, Hepatic metastases, Treatment withdrawn

Référence

Clin Breast Cancer. 2022 10 13;: